Literature DB >> 15837248

Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial.

Stephen G Ellis1, Jeffrey J Popma, John M Lasala, Joerg J Koglin, David A Cox, James Hermiller, Charles O'shaughnessy, James Tift Mann, Mark Turco, Ronald Caputo, Patrick Bergin, Joel Greenberg, Gregg W Stone.   

Abstract

OBJECTIVES: We sought to evaluate the relationship between angiographic late loss and clinical outcomes in the drug-eluting stent era.
BACKGROUND: The interrelationship between angiographic late loss, binary restenosis, and clinical recurrence (target lesion revascularization [TLR]) after coronary stent implantation has been incompletely evaluated.
METHODS: Using the angiographic substudy of the TAXUS-IV trial, in which 1,314 patients with de novo coronary lesions were randomized to either the paclitaxel-eluting TAXUS stent or to its bare-metal equivalent, we defined the relationship between in-stent and analysis segment late loss, the shape of the late loss histogram (variance and skewedness), and nine-month TLR.
RESULTS: Late loss by several measures was closely related to TLR (area under the receiver-operator curve >0.90). For individual vessels of the size in this study (2.8 +/- 0.5 mm), the likelihood of TLR did not exceed 5% until analysis segment late loss was >0.5 mm, and did not exceed 10% until late loss was >0.65 mm. At greater late losses, the late loss TLR relationship was steep and nearly linear. For the overall patient cohort, the rate of TLR was related, however, not only to median late loss, but also to measures of its statistical distribution (TLR increased with lack of homogeneous biologic response [greater variance and greater right skewedness]). Similar relationships held for late loss measured within the confines of the stent itself.
CONCLUSIONS: Coronary stents result in large lumens with "room" to accommodate up to approximately 0.5 to 0.65 mm of tissue (angiographic analysis segment late loss) before the likelihood of clinical restenosis (TLR) exceeds 5% to 10%. These data have important implications toward understanding the absolute and relative efficacy of drug-eluting stents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837248     DOI: 10.1016/j.jacc.2004.11.063

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

1.  Clinical outcomes of left main crossover stenting for ostial left anterior descending artery acute myocardial infarction.

Authors:  Kei Yamamoto; Kenichi Sakakura; Naoyuki Akashi; Yusuke Watanabe; Masamitsu Noguchi; Yousuke Taniguchi; Hiroshi Wada; Shin-Ichi Momomura; Hideo Fujita
Journal:  Heart Vessels       Date:  2017-08-03       Impact factor: 2.037

Review 2.  Percutaneous coronary interventions with drug eluting stents for diabetic patients.

Authors:  Ricardo Seabra-Gomes
Journal:  Heart       Date:  2006-03       Impact factor: 5.994

3.  Correlation of angiographic late loss with neointimal coverage of drug-eluting stent struts on follow-up optical coherence tomography.

Authors:  Byeong-Keuk Kim; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  Int J Cardiovasc Imaging       Date:  2011-08-24       Impact factor: 2.357

4.  Comparison of mid-term clinical outcomes between on-label and off-label use of rotational atherectomy.

Authors:  Takayuki Mori; Kenichi Sakakura; Hiroshi Wada; Yousuke Taniguchi; Kei Yamamoto; Yusuke Adachi; Hiroshi Funayama; Shin-Ichi Momomura; Hideo Fujita
Journal:  Heart Vessels       Date:  2016-10-05       Impact factor: 2.037

5.  Comparison of long-term clinical outcomes between sirolimus- and paclitaxel-eluting stents in real-world clinical practice.

Authors:  Ryo Naito; Katsumi Miyauchi; Hirokazu Konishi; Shuta Tsuboi; Manabu Ogita; Takatoshi Kasai; Hiroshi Tamura; Shinya Okazaki; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2014-08-13       Impact factor: 2.037

6.  [New developments in drug-eluting stents].

Authors:  M Kollum; C Bode
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

Review 7.  Small vessel coronary artery disease: How small can we go with myocardial revascularization?

Authors:  Maciej T Wybraniec; Paweł Bańka; Tomasz Bochenek; Tomasz Roleder; Katarzyna Mizia-Stec
Journal:  Cardiol J       Date:  2020-09-28       Impact factor: 2.737

Review 8.  Small coronary vessel angioplasty: outcomes and technical considerations.

Authors:  Sudhir Rathore
Journal:  Vasc Health Risk Manag       Date:  2010-10-21

9.  Low resolution limits and inaccurate algorithms decrease significantly the value of late loss in current drug-eluting stent trials.

Authors:  Johannes B Dahm; Frank van Buuren
Journal:  Int J Vasc Med       Date:  2012-03-20

10.  A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program.

Authors:  Dominic J Allocco; Louis A Cannon; Amy Britt; John E Heil; Andrey Nersesov; Scott Wehrenberg; Keith D Dawkins; Dean J Kereiakes
Journal:  Trials       Date:  2010-01-07       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.